INCR
InterCure Ltd.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · IL
$5.45
+3.61%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−6.9x
Market Cap
$81.77M
MomentumView details →
1D Return
+3.61%
YTD Return
+18.79%
RSI (14)
54.9
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−6.9x
Market Cap
$81.77M
RSI (14)
54.9
MomentumView details →
1D Return
+3.61%
YTD Return
+18.79%
SummaryUpdated Dec 1, 2025
InterCure Ltd. (NASDAQ:INCR) is an Israeli medical cannabis company founded in 1994 and headquartered in Herzliya, Israel. The company went public on NASDAQ in January 2019. InterCure has evolved from its original incorporation to become one of the largest medical cannabis companies outside North America, focusing on pharmaceutical-grade cannabis products for medical use. The company operates primarily in Israel while expanding internationally into European markets including the UK, Germany, and Austria.
Similar companies
Latest newsMore news →
InterCure finalized a NIS 230 million (~US$77 million) settlement for war-related indirect damages, and plans to accelerate rehabilitation of Canndoc's Nir Oz facility.11d agoInterCure Ltd. secured NIS 22 million in private placement financing from investors including its CEO and pharma-focused hedge funds.74d agoInterCure completed the initial closing of its acquisition of Botanico, gaining exclusive access to U.S. genetics, premium brands, and AI-driven technologies.81d ago